Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Oncology Subcmte. Should Discuss Timing Of Studies – Workshop

Executive Summary

The Pediatric Oncology Subcommittee should determine when it is appropriate to initiate clinical testing of oncologic agents in children, participants at an FDA workshop on pediatric oncology drug development agreed
Advertisement

Related Content

Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds
Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds
Cancer Drug Accelerated Approval Could Be Based On Pediatric Studies
Pediatric Oncology Trials Should Start After Adult Phase I Data – Subcmte.
FDA Pediatric Therapeutics Office To Consider Ethics, Postmarket Safety
AstraZeneca Iressa NDA Filing Complete: Will HIV Model Fly In Oncology?
FDA Role In Prioritizing Pediatric Oncologic Development On Cmte. Agenda
FDA Pediatric Oncology Workshop Will Define Advisory Committee Mission
FDA Pediatric Oncology Workshop Will Define Advisory Committee Mission
Cancer Expanded Access Plans Need Focus On Data Collection – FDA’s Pazdur
Advertisement
UsernamePublicRestriction

Register

PS040312

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel